Enlivex (ENLV) Income from Non-Controlling Interests (2017 - 2021)
Enlivex (ENLV) posted quarterly Income from Non-Controlling Interests of -$2.8 million for Q1 2021, down 174.41% year-over-year from $3.7 million in Q1 2020, and down 174.41% quarter-over-quarter from -$1.0 million in Q1 2020.
Enlivex (ENLV) Income from Non-Controlling Interests (2017 - 2021) Analysis & Trends
Enlivex's Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at -$2.8 million for Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 2.06 Mn |
| Mar 31, 2021 | -2.79 Mn |
| Mar 31, 2020 | -1.02 Mn |
| Sep 30, 2019 | 350,000.00 |
| Jun 30, 2019 | 234,000.00 |
| Mar 31, 2019 | 300,000.00 |
| Sep 30, 2018 | -40,000.00 |
| Jun 30, 2018 | -272,000.00 |
| Mar 31, 2018 | -99,000.00 |
| Sep 30, 2017 | -33,000.00 |